GSK shares platform with a Chinese biotech to boost vaccine development
GSK is giving Clover Biopharmaceuticals the proverbial keys to its proprietary adjuvant platform so that the Chinese biotech can develop a vaccine against Covid-19, the disease caused by the coronavirus circulating now in China and elsewhere.
As STAT’s Andrew Joseph reports, while GSK is not developing its own vaccine, the U.K. pharma giant said earlier this month that it would offer its platform to others, in collaboration with the Coalition for Epidemic Preparedness Innovations.
“The use of an adjuvant is of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protect more people,” Thomas Breuer, the chief medical officer of GSK Vaccines, said in a statement.
As STAT’s Andrew Joseph reports, while GSK is not developing its own vaccine, the U.K. pharma giant said earlier this month that it would offer its platform to others, in collaboration with the Coalition for Epidemic Preparedness Innovations.
“The use of an adjuvant is of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protect more people,” Thomas Breuer, the chief medical officer of GSK Vaccines, said in a statement.
.png)
No hay comentarios:
Publicar un comentario